BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES
BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES Dr. W. Randolph Ford, Ph.D., will be joining BioMark’s Advisory team to support Artificial Intelligence and Machine Learning capabilities. Vancouver, British Columbia – (November 14th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy […]
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST Vancouver, British Columbia and Québec City, Québec – (November 7, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a leading liquid biopsy company focusing on metabolomics for the early diagnosis of […]
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark’s liquid biopsy platform beyond early lung cancer detection. Vancouver, British Columbia – (October 24th, 2023) – BioMark Diagnostics Inc. […]
Form 7 Monthly Progress Report October 2023
Form 7 Monthly Progress Report October 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 November 3, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report September 2023
Form 7 Monthly Progress Report September 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 October 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis This article recently appeared in the French-Canadian news publication “Le Soleil”. The origjnal article can be found here: https://www.lesoleil.com/affaires/2023/08/30/une-technologie-dici-pour-mieux-diagnostiquer-le-cancer-du-poumon-WMYOCY325FC65HU4ISBUQWJT5U/ The following is an AI translation of the text of the article to English: “Local Technology for Improved […]
BioMark appointS Kevin J. Cosgriff TO ITS STRATEGIC Advisory Team
Vancouver, British Columbia – (August 30th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark’s Advisory team to support its innovation and […]
Form 7 Monthly Progress Report August 2023
Form 7 Monthly Progress Report August 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 September 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
JAPAN PATENT OFFICE (JPO) ISSUEDD BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY
JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY New family of patent granted by Japanese Patent Office enhances BioMark’s global intellectual property position in lung cancer detection using urine as a convenient biological sample medium. Vancouver, British Columbia – (August 8th, 2023) – BioMark Diagnostics […]
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update Vancouver, British Columbia – (July 25th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity. […]
